NKI

RootPath Announces Publication Demonstrating How Its Novel Gene Synthesis Technology Empowers Cell Therapy in Solid Tumor Cancers

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Nature Medicine, NKI, Cell, Nature Biotechnology, TILS, Research, Patient, Netherlands Cancer Institute, Synthetic biology, Discovery, Neoplasm, TCR, Growth, Gene, Fine chemical

RootPath , a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced a new publication in Nature Biotechnology detailing research that demonstrates the power of the company’s novel gene synthesis technology and how it may contribute to successful cell therapy in solid tumor cancers.

Key Points: 
  • RootPath , a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced a new publication in Nature Biotechnology detailing research that demonstrates the power of the company’s novel gene synthesis technology and how it may contribute to successful cell therapy in solid tumor cancers.
  • The publication is titled “ Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening ”.
  • With the help of RootPath’s innovative synthesis technology, we now improved the throughput of this approach by a factor of 100.
  • The company will soon offer TCR gene synthesis and screening services commercially, as reported in the study.

 Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Toxicity, Netherlands Cancer Institute, VLS, Therapeutic index, Cell, Patient, ICB, Neoplasm, Immunology, Hypertelorism, Cancer, Infection, Publication, Immunity, IL-2, NKI, CD8, Immune system, Division, NK, Autoimmunity, PD-1, Vaccine

The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.

Key Points: 
  • The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.
  • “These co-published manuscripts are the culmination of several years of great collaboration between Asher Bio scientists and our academic co-founders, Dr.
  • Asher Bio systematically evaluated the properties needed for effective cis-targeting to CD8+ T cells and generated AB248, a CD8+ T cell selective IL-2.
  • To evaluate this hypothesis, Asher Bio’s collaborators at the NKI performed a comprehensive analysis of T cell reinvigoration following treatment with AB248.

Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research

Retrieved on: 
Friday, April 5, 2024
ACT, Lung cancer, Netherlands Cancer Institute, Risk, Patient, DNA, Research, Bladder cancer, NKI, MRD, Liquid biopsy, Recurrence, Plasma, Neoplasm, Medical imaging

BURLINGTON, N.C., April 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular residual disease (MRD) solution in early stage colon cancer to identify patients at increased risk of recurrence after surgery or adjuvant chemotherapy (ACT). This solution, which is designed for research use but also suitable for clinical applications, can be applied across solid tumors with a scalable and standardized approach to facilitate faster turnaround times while maintaining high analytical performance.

Key Points: 
  • The launch of the Labcorp Plasma Detect MRD solution further enhances Labcorp's leadership in precision oncology across the solid tumor oncology care continuum.
  • Labcorp Plasma Detect builds on the successful deployment of two existing liquid biopsy platforms – Labcorp® Plasma Focus™, a targeted approach, and Labcorp® Plasma Complete™, a comprehensive profiling solution, both with utility for clinical research and clinical applications.
  • "Labcorp Plasma Detect delivers a high-impact solution for clinical research and biopharmaceutical drug development to support retrospective and prospective clinical trials with the goal of improving patient outcomes in early stage disease."
  • Labcorp Plasma Detect is currently clinically validated for early-stage colon cancer, with ongoing efforts to expand into other indications, including lung cancer and bladder cancer.

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Retrieved on: 
Monday, November 13, 2023
Doxorubicin, Squamous-cell carcinoma, Research, Netherlands Cancer Institute, City, Progression-free survival, Sarcoma, BioRxiv, Clinical trial, Patient, Northwestern, MD Anderson Cancer Center, GEIS, Monroe Dunaway Anderson, GSK, PP2A, ASTS, Sarah Cannon Research Institute, SCRI, Cancer, University, Partnership, NKI, Immunotherapy, Pharmaceutical industry

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.

Key Points: 
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.
  • GSK will provide dostarlimab and financial support for the clinical trial.
  • In addition to MD Anderson, the trial also will be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
  • This trial will enroll up to 170 patients and will begin in partnership with GEIS clinical sites.

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

Retrieved on: 
Monday, October 23, 2023
Patient, NKI, Ovarian cancer, ESMO, American Society of Clinical Oncology, BioNTech, RNA, DCR, Neurotoxicity, Entrepreneurship, Society, CLDN6, Annual general meeting, Tumor antigen, ORR, Netherlands Cancer Institute, BNTX, Safety, ASCO, Vaccine, Pharmaceutical industry

The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac.

Key Points: 
  • The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac.
  • “Our goal is to unlock the potential of CAR-T for solid tumors and to help improve the outcomes for a broad range of hard-to-treat tumors,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech.
  • “BNT211 aims to address two of the key limitations of CAR-T cell approaches in solid tumors, namely the lack of suitable cancer-specific cell surface targets and the limited persistence of CAR-T cells.
  • Patients with germ cell tumors (n=16), ovarian cancer (n=17) and other solid tumor types (n=11) were treated.

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

Retrieved on: 
Monday, October 16, 2023
Cancer, NKI, Research, PP2A, Netherlands Cancer Institute, Drug combination, Immunotherapy, Patient, Pharmaceutical industry

PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers. The new agreement also will seek to find synthetic lethal combinations in additional cancer types.

Key Points: 
  • PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers.
  • The new agreement also will seek to find synthetic lethal combinations in additional cancer types.
  • NKI, based in Amsterdam, Netherlands, is among the world’s leading comprehensive cancer centers.
  • Oncode Institute, headquartered in Utrecht, Netherlands, is a major independent cancer research center dedicated to translating research into practice and bringing discoveries into a clinic setting more quickly.

Netherlands Cancer Institute (NKI) Selects Proscia To Drive Personalized Diagnosis

Retrieved on: 
Wednesday, January 18, 2023
Digital, Marie Cassidy, COVID-19, Public health, Biomedical Research, Pathology, Netherlands Cancer Institute, Precision medicine, IVDR, Diagnosis, Patient, DX, Research, NKI, Health, Medical imaging

AMSTERDAM and PHILADELPHIA, Jan. 18, 2023 /PRNewswire-PRWeb/ -- Proscia®, a leading provider of digital and computational pathology solutions, today announced that the Netherlands Cancer Institute (NKI), one of the top 10 comprehensive cancer centers in Europe, will deploy its Concentriq® Dx platform. NKI is transitioning to Concentriq Dx to expand its digital pathology practice, laying the foundation for its pathologists to deliver personalized diagnoses that better inform treatment decisions. In doing so, the cancer center, which houses an internationally acclaimed research institute, will generate additional pathology data that can lead to clinical breakthroughs.

Key Points: 
  • AMSTERDAM and PHILADELPHIA, Jan. 18, 2023 /PRNewswire-PRWeb/ -- Proscia® , a leading provider of digital and computational pathology solutions, today announced that the Netherlands Cancer Institute (NKI), one of the top 10 comprehensive cancer centers in Europe, will deploy its Concentriq® Dx platform.
  • In doing so, the cancer center, which houses an internationally acclaimed research institute, will generate additional pathology data that can lead to clinical breakthroughs.
  • "The modern, enterprise-grade platform will enable us to increasingly combine expertise and insight to drive precision diagnosis.
  • *Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.

Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors

Retrieved on: 
Tuesday, May 10, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Gene, Population, NKI, Neoplasm, Safety, TP53, Probability, CTA, Patient, TCR, Netherlands Cancer Institute, Partnership, Adult, HLA, Research, Growth, KRAS, Therapy, Pharmaceutical industry, Neogene

The Phase 1 study will enroll adult patients with various types of advanced solid tumors in partnership with the Netherlands Cancer Institute (NKI), an internationally acclaimed research institute and leading cancer clinic.

Key Points: 
  • The Phase 1 study will enroll adult patients with various types of advanced solid tumors in partnership with the Netherlands Cancer Institute (NKI), an internationally acclaimed research institute and leading cancer clinic.
  • NT-125 is an investigational, autologous, fully-individualized, multi-specific TCR therapy targeting neoantigens for the treatment of advanced solid tumors.
  • Patients with recurrent and metastatic solid tumors currently have a high unmet need and limited effective treatment options.
  • Neogene is a global biotechnology company focused on discovering, developing, and manufacturing novel, transformative TCR therapies targeting neoantigens in solid cancers.

LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations

Retrieved on: 
Tuesday, April 12, 2022
Treatment, CEO, DNA, Marketing, Annual general meeting, Association, Research, U.S. Securities and Exchange Commission, Toxicity, Diagnosis, CA, Creativity, GLOBE, Terminology, Drug combination, Drug Quality and Security Act, Cell, Patient, WEE1, Securities Exchange Act of 1934, Company, PP2A, Colorectal cancer, DNA repair, NKI, Cancer, Securities Act of 1933, AACR Awards, Netherlands Cancer Institute, KRAS, AACR, CRISPR, Pharmaceutical industry

AACR is the largest cancer research organization in the world, with more than 50,000members residing in 129 countries and territories.

Key Points: 
  • AACR is the largest cancer research organization in the world, with more than 50,000members residing in 129 countries and territories.
  • His creativity in developing new anti-cancer drug combinations has already had a significant impact on cancer care.
  • ( Nasdaq: LIXT ), is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies.
  • Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements.

BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR

Retrieved on: 
Monday, April 11, 2022
Company, Private Securities Litigation Reform Act, Immunotherapy, CLDN6, Clinical trial, Netherlands Cancer Institute, Sarcoma, CAR, SEC, BioNTech, Program, Neoplasm, Fallopian tube cancer, Cancer, RNA, Deepening, Entrepreneurship, Regeneron Pharmaceuticals, Ovarian cancer, NKI, Hoffmann-La Roche, Endometrial cancer, Safety, Review, Hematological Cancer Research Investment and Education Act, RNA transfection, Stomach, Nasdaq, Geneve L. A. Shaffer, GLOBE, Toxic shock syndrome, Testicular cancer, BNTX, Nature, Annual report, Patient, Infection, Vaccine, Medical imaging, Pharmaceutical industry, Genentech, Pfizer

The preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of BNT211.

Key Points: 
  • The preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of BNT211.
  • The data were presented in the Clinical Trials Plenary Session at the AACR Annual Meeting 2022 by Prof. John Haanen, M.D., Ph.D., Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.
  • Tumor indications included testicular cancer (n=8) ovarian cancer (n=4), endometrial cancer, fallopian tube cancer, sarcoma, and gastric cancer (1 patient each).
  • Our preliminary data indicate that the successes of CAR-T in hematological cancers may indeed be transferred to solid tumors.